StreetInsider.com News Articles

AngioDynamics reports pancreatic IRE study results and new CPT code

Wed, 21 Oct 2026 08:31:32 -0400

AngioDynamics, Inc. (NASDAQ: ANGO) announced the publication of results from the DIRECT study in The Oncologist and the establishment of a new Category I CPT code for open irreversible electroporation (IRE) ablation of pancreatic tumors, effective January 1, 2027.

The DIRECT study, conducted under a U.S. Food and Drug Administration Investigational Device Exemption across 18 U.S. sites, analyzed 137 patients with Stage III pancreatic ductal adenocarcinoma. Of those, 99 were treated with standard-of-care systemic therapy plus IRE, and 38 received standard-of-care therapy without IRE.

Patients in the IRE group had a median overall survival of 28 months from diagnosis, compared with 15

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

Wed, 21 Oct 2026 08:30:00 -0400

Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer; new Category I CPT code for open pancreatic IRE takes effect January 1, 2027

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

Wed, 21 Oct 2026 08:30:00 -0400

AngioDynamics (ANGO) PT Lowered to $18 at H.C. Wainwright

Wed, 14 Oct 2026 07:17:53 -0400

(Updated - October 14, 2026 7:17 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on AngioDynamics (NASDAQ: ANGO) to $18.00 (from $19.00) while maintaining a Buy rating.

The analyst commented: "Last week, AngioDynamics reported its financial results for fiscal 1Q27 ending on August 31, 2026. Net sales were $80.9M, representing 6.9% YoY growth and in line with our projection of $81.0M. Specifically, Med Tech sales were $39.9M (up 13.2% YoY) and Med Device sales were $41.0M (up 1.4% YoY). Net loss was $7.1M, or ($0.17) per share, less than our estimated loss of $12.9M. Adjusted net loss was $1.8M,

AngioDynamics (ANGO) PT Lowered to $18 at H.C. Wainwright

Wed, 14 Oct 2026 07:17:53 -0400

(Updated - October 14, 2026 7:17 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on AngioDynamics (NASDAQ: ANGO) to $18.00 (from $19.00) while maintaining a Buy rating.

Humana to cover AngioDynamics NanoKnife for prostate, liver cancer

Wed, 14 Oct 2026 07:01:56 -0400

AngioDynamics, Inc. (NASDAQ: ANGO) announced that Humana has updated its Medicare Advantage coverage policy to include irreversible electroporation (IRE) treatment delivered by the NanoKnife System for eligible patients with intermediate-risk prostate cancer and certain liver tumors, effective October 1, 2026.

The Humana policy applies Local Coverage Determination (LCD) L40205 medical necessity criteria across Medicare Administrative Contractor jurisdictions. Coverage applies to patients with favorable intermediate-risk prostate cancer, Grade Group 2, and to patients with metastatic colorectal cancer to the liver who cannot be safely resected or treated with margin-negative thermal ablation. Coverage remains subject to Humana's prior authorization process and individual plan

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

Wed, 14 Oct 2026 07:00:00 -0400

Policy Applies Medical Necessity Criteria Across Medicare Administrative Contractor (MAC) Jurisdictions for Eligible Prostate and Liver Cancer Patients

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation technology delivered by AngioDynamics’ NanoKnife System, for eligible patients with intermediate-risk prostate cancer and certain

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

Wed, 14 Oct 2026 07:00:00 -0400

Policy Applies Medical Necessity Criteria Across Medicare Administrative Contractor (MAC) Jurisdictions for Eligible Prostate and Liver Cancer Patients

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation technology delivered by AngioDynamics’ NanoKnife System, for eligible patients with intermediate-risk prostate cancer and certain

Canaccord Reiterates Buy Rating on AngioDynamics (ANGO)

Fri, 09 Oct 2026 07:06:31 -0400

Canaccord analyst William Plovanic reiterated a Buy rating and $20.00 price target on AngioDynamics (NASDAQ: ANGO).

The analyst commented: "We see no fundamental reason for today’s weakness in ANGO shares following an in-line FQ1 print and reiterated guidance. We continue to see growth across the three Med Tech platforms, Auryon, NanoKnife, and Mechanical Thrombectomy, each of which has near-term growth catalysts and is backed by long-term R&D investment. ANGO delivered $80.9M (+6.9%) in revenue, in line with CGe and consensus estimates, although the mix of Med Tech platform revenue differed from our model (see more below). Auryon was the best performer

AngioDynamics (ANGO) October 12.50 calls active

Fri, 09 Oct 2026 05:04:59 -0400

AngioDynamics (NASDAQ: ANGO) 30-day option implied volatility is at 50; compared to its 52-week range of 34 to 80 with a focus on October 12.50 calls.

Form 10-Q ANGIODYNAMICS INC For: Aug 31

Thu, 08 Oct 2026 12:57:00 -0400

si-local-file:///var/storage/secattach/20261008/27166076.html

Form DEFA14A ANGIODYNAMICS INC

Thu, 08 Oct 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20261008/27165329.html

Form DEF 14A ANGIODYNAMICS INC For: Nov 17

Thu, 08 Oct 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20261008/27164181.html

AngioDynamics stock slips 4% despite beating estimates on Med Tech growth

Thu, 08 Oct 2026 07:38:12 -0400

Investing.com -- On Wednesday, AngioDynamics Inc. (NASDAQ:ANGO) reported first quarter fiscal 2027 results that exceeded analyst expectations, with adjusted loss per share of -$0.04 compared to the consensus estimate of -$0.11 and revenue of $80.9 million versus the estimate of $80.5 million.

Shares of the medical technology company slid down -4.26% in pre-market trading following the release.

The company’s revenue increased 6.9% YoY, driven by its Med Tech segment, which grew 13.2% to $39.9 million. This marked the eighth consecutive quarter of double-digit Med Tech growth. The Med Device segment posted $41.0 million in sales, up 1.4% YoY. Gross

AngioDynamics stock slips 4% despite beating estimates on Med Tech growth

Thu, 08 Oct 2026 07:38:12 -0400

Shares of the medical technology company slid down -4.26% in pre-market trading following the release.

Form 8-K ANGIODYNAMICS INC For: Oct 08

Thu, 08 Oct 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20261008/27163567.html

Form 8-K ANGIODYNAMICS INC For: Oct 02

Thu, 08 Oct 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20261008/27163562.html

AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance

Thu, 08 Oct 2026 06:05:08 -0400

AngioDynamics (NASDAQ: ANGO) reported Q1 EPS of ($0.04), $0.07 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $80.9 million versus the consensus estimate of $80.5 million.

GUIDANCE:

AngioDynamics sees FY2027 EPS of ($0.29)-($0.24). AngioDynamics sees FY2027 revenue of $336-341 million, versus the consensus of $337.32 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance

Thu, 08 Oct 2026 06:05:08 -0400

GUIDANCE:

AngioDynamics sees FY2027 EPS of ($0.29)-($0.24). AngioDynamics sees FY2027 revenue of $336-341 million, versus the consensus of $337.32 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

Thu, 08 Oct 2026 06:02:00 -0400

Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA

Fiscal Year 2027 First Quarter Financial Highlights

Quarter Ended
August 31, 2026

Medical Technology Executive Brings More than 20 years of Leadership Experience, Including Cardiovascular, Endovascular and Oncology Markets, with a Track Record of Accelerating Growth and Improving Profitability

Jim Clemmer to Retire Following Ten Years as President and Chief Executive Officer

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

Thu, 08 Oct 2026 06:00:00 -0400

Jim Clemmer to Retire Following Ten Years as President and Chief Executive Officer

AngioDynamics funds Jacobi Hospital PE imaging research

Fri, 02 Oct 2026 06:03:26 -0400

AngioDynamics, Inc. (NASDAQ: ANGO) and The PERT Consortium® have selected Jacobi Hospital in the Bronx, New York, as a recipient of an ALPHA-PE Research Fund award, according to a press release from the company.

The award will fund an independent, investigator-led study by Dr. Jonathan Alis, Dr. Seth I. Sokol and their team. The study will evaluate CT pulmonary angiography radiomics as predictors of thrombus biology, thrombectomy success and long-term outcomes in patients with pulmonary embolism (PE).

The research will assess imaging biomarkers that may reflect clot composition and predict how a patient's clot responds to mechanical thrombectomy. Physicians currently have limited